Medically reviewed by Jonathan Hansen, MD, PhD

Often, immune-system-suppressing medications are the next step in treatment for people with IBD who have tried non-immune suppressing medications like aminosalicylates/5-ASAs without success, or for people who are depending on corticosteroids like prednisone to maintain remission.

Some immune-system-suppressing medications are taken as pills and others are taken as shots. The two most commonly prescribed immune system suppressors in pill form are azathioprine (AZA, brand names Imuran® and Azasan®) and 6-mercaptopurine (6-MP, brand name Purinethol®), also known as immunomodulators. These drugs have been used to treat IBD and other autoimmune conditions since the late 1960s. Interestingly, they were initially designed to prevent organ rejection in patients who received a transplant. (You may hear people say that these drugs are “chemotherapy,” but this is not accurate.)

Common Uses in IBD

As the name implies, immune system suppressors weaken or suppress the activity of the body’s immune system, which is considered to be overactive in people suffering from IBD. Though it is unclear exactly how immunomodulators suppress the immune system, it is thought that they may do so by reducing the quantity and/or functioning of inflammatory white blood cells in the body.

In general, these pills are most effective at maintaining—rather than inducing—remission for both ulcerative colitis and Crohn’s disease. Because immunomodulators can require at least three months to take effect, they are often prescribed in addition to a faster-acting drug, such as corticosteroids. Taking both drugs simultaneously also allows people to take a lower dosage of steroids, which in turn reduces the side effects from the steroids and allows the steroids to be stopped altogether more quickly. In this way, immunomodulators can reduce the chances of more serious long-term side effects associated with steroids.

Effectiveness of Immunomodulators

For people with Crohn’s disease, immunomodulators effectively maintain remission to at least a small degree. In a paper published in the October 2015 Cochrane Database of Systematic Reviews, researchers assessed data from 489 participants of six different studies, and found that azathioprine (one of the two most common immunomodulators used for IBD) was significantly more effective than a placebo for maintaining remission for 6 to 18 months, helping maintain remission for 73% of the azathioprine-treated patients vs. 62% of those taking a placebo.

The difference was even more dramatic for people with ulcerative colitis: Authors of a similar Cochrane Review paper published in 2015 found that in seven studies, which included a total of 302 people with ulcerative colitis, 66% of patients on immunomodulators maintained a remission, compared with 35% of patients taking a placebo.

However, there is one distinct group of people for whom immunomodulators do not seem to help maintain remission from IBD. It seems that these people’s bodies break down immunomodulators into inactive components that are not effective for treating IBD. Your doctor may consider running a blood test to find out if you belong to this group.


Tara Baukus Mello

With more than 4,000 articles to her credit, Tara Baukus Mello’s work has appeared in such publications as Woman’s Day, The New York Times, The Los Angeles Times, and cNet.com, among others.

Medical reviewer and Oshi physician-partner Jonathan Hansen, MD, PhD, has been involved in 20-plus clinical trials of investigational compounds that target various pathways important in the development of IBD. He has co-authored book chapters on IBD and been published in a variety of peer-reviewed journals, and his interests include the role of environmental bacteria in the development of chronic intestinal inflammation. Dr. Hansen serves as an Associate Professor of Medicine in the Division of Gastroenterology & Hepatology at the University of North Carolina at Chapel Hill. He received his BS in Biochemistry from Brigham Young University, and his MD and PhD in Microbiology and Immunology from Indiana University School of Medicine.

Oshi is a tracking tool and content resource. It does not render medical advice or services, and it is not intended to diagnose, treat, cure, or prevent any disease. You should always review this information with your healthcare professionals.